throbber
HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`These highlights do not include all the information needed to use
`
`AFINITOR safely and effectively. See full prescribing information for
`
`AFINITOR.
`
`AFINITOR® (everolimus) tablets for oral administration
`AFINITOR® DISPERZ (everolimus tablets for oral suspension)
`
`Initial U.S. Approval: 2009
`
`----------------------------RECENT MAJOR CHANGES-------------------------­
`
`
`Warnings and Precautions, Angioedema (5.3)
`1/2015
`
`----------------------------INDICATIONS AND USAGE--------------------------­
`
`AFINITOR is a kinase inhibitor indicated for the treatment of:
` postmenopausal women with advanced hormone receptor-positive, HER2­
`
`negative breast cancer (advanced HR+ BC) in combination with
`
`exemestane after failure of treatment with letrozole or anastrozole. (1.1)
`
` adults with progressive neuroendocrine tumors of pancreatic origin (PNET)
`
`that are unresectable, locally advanced or metastatic. AFINITOR is not
`
`indicated for the treatment of patients with functional carcinoid tumors.
`(1.2)
` adults with advanced renal cell carcinoma (RCC) after failure of treatment
`with sunitinib or sorafenib. (1.3)
`
` adults with renal angiomyolipoma and tuberous sclerosis complex (TSC),
`
`
`not requiring immediate surgery. The effectiveness of AFINITOR in the
`treatment of renal angiomyolipoma is based on an analysis of durable
`objective responses in patients treated for a median of 8.3 months. Further
`
`follow-up of patients is required to determine long-term outcomes. (1.4)
`
`AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the
`treatment of:
`
` pediatric and adult patients with tuberous sclerosis complex (TSC) who
`
`have subependymal giant cell astrocytoma (SEGA) that requires
`therapeutic intervention but cannot be curatively resected. The
`effectiveness is based on demonstration of durable objective response, as
`evidenced by reduction in SEGA tumor volume. Improvement in disease-
`related symptoms and overall survival in patients with SEGA and TSC has
`
`not been demonstrated. (1.5)
`
`------------------------DOSAGE AND ADMINISTRATION--------------------­
`Advanced HR+ BC, advanced PNET, advanced RCC, or renal
`angiomyolipoma with TSC:
`
` 10 mg once daily with or without food. (2.1)
`
`
`
` For patients with hepatic impairment, reduce the AFINITOR dose. (2.2)
`
`
` If moderate inhibitors of CYP3A4 /P-glycoprotein (PgP) are required,
`
`
`
`reduce the AFINITOR dose to 2.5 mg once daily; if tolerated, consider
`
`increasing to 5 mg once daily. (2.2)
`
`
` If strong inducers of CYP3A4 are required, consider doubling the daily
`
`
`dose of AFINITOR using increments of 5 mg or less. (2.2)
`
`
`SEGA with TSC:
`
` 4.5 mg/m2 once daily; adjust dose to attain trough concentrations of 5-15
`
`ng/mL. (2.3)
`
` Assess trough concentrations approximately 2 weeks after initiation of
`
`treatment, a change in dose, a change in co-administration of CYP3A4
`/PgP inducers or inhibitors, a change in hepatic function, or a change in
`dosage form between AFINITOR Tablets and AFINITOR DISPERZ. (2.3,
`
`2.4)
`
` For patients with severe hepatic impairment reduce the starting dose of
`
`AFINITOR Tablets or AFINITOR DISPERZ. (2.3, 2.5)
`
` If concomitant use of moderate inhibitors of CYP3A4 /PgP is required,
`
`
`reduce the dose of AFINITOR Tablets or AFINITOR DISPERZ by 50%.
`
`(2.3, 2.5)
`
` If concomitant use of strong inducers of CYP3A4/PgP is required, double
`
`the dose of AFINITOR Tablets or AFINITOR DISPERZ. (2.3, 2.5)
`
`
`----------------------DOSAGE FORMS AND STRENGTHS--------------------­
`AFINITOR Tablets: 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets with no score
`(3.1)
`
`
`
`
`
`
`
`AFINITOR DISPERZ (everolimus tablets for oral suspension): 2 mg, 3 mg,
`
`
`and 5 mg tablets for oral suspension with no score (3.2)
`-------------------------------CONTRAINDICATIONS-----------------------------­
`Hypersensitivity to everolimus, to other rapamycin derivatives, or to any of
`the excipients (4)
`
`-----------------------WARNINGS AND PRECAUTIONS-----------------------­
`
` Non-infectious pneumonitis: Monitor for clinical symptoms or radiological
`
`changes; fatal cases have occurred. Manage by dose reduction or
`
`
`discontinuation until symptoms resolve, and consider use of
`corticosteroids. (5.1)
` Infections: Increased risk of infections, some fatal. Monitor for signs and
`symptoms, and treat promptly. (5.2)
` Angioedema: Patients taking concomitant ACE inhibitor therapy may be at
`
`increased risk for angioedema. (5.3)
`
` Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.
`
`
`Management includes mouthwashes and topical treatments. (5.4)
` Renal failure: Cases of renal failure (including acute renal failure), some
`
`
`with a fatal outcome, have been observed. (5.5)
` Impaired wound healing: Increased risk of wound-related complications.
`
`
`Monitor signs and symptoms. Exercise caution in the peri-surgical period.
`
`(5.6)
` Laboratory test alterations: Elevations of serum creatinine, urinary protein,
`
`
`blood glucose, and lipids may occur. Decreases in hemoglobin, neutrophils,
`
`
`and platelets may also occur. Monitor renal function, blood glucose, lipids,
`
`
`
`and hematologic parameters prior to treatment and periodically thereafter.
`(5.8)
` Vaccinations: Avoid live vaccines and close contact with those who have
`
`received live vaccines. (5.11)
`
` Embryo-fetal toxicity: Fetal harm can occur when administered to a
`
`
`pregnant woman. Apprise women of potential harm to the fetus. (5.12, 8.1)
`
`
`------------------------------ADVERSE REACTIONS------------------------------­
`
`Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse
`reactions (incidence ≥30%) include stomatitis, infections, rash, fatigue,
`diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and
`
`decreased appetite. (6.1, 6.2, 6.3)
`Renal angiomyolipoma with TSC: Most common adverse reaction (incidence
`≥ 30%) is stomatitis. (6.4)
`
`SEGA with TSC: Most common adverse reactions (incidence ≥ 30%) are
`
`stomatitis and respiratory tract infection. (6.5)
`To report SUSPECTED ADVERSE REACTIONS, contact Novartis
`
`Pharmaceuticals Corporation at 1-888-669-6682 or FDA at
`1-800-FDA-1088 or www.fda.gov/medwatch.
`
`
`------------------------------DRUG INTERACTIONS------------------------------­
`
` Strong CYP3A4/PgP inhibitors: Avoid concomitant use. (2.2, 2.5, 5.9, 7.1)
` Moderate CYP3A4/PgP inhibitors: If combination is required, use caution
`and reduce dose of AFINITOR. (2.2, 2.3, 2.5, 5.9, 7.1)
`
`
` Strong CYP3A4/PgP inducers: Avoid concomitant use. If combination
`
`cannot be avoided, increase dose of AFINITOR. (2.2, 2.3, 2.5, 5.9, 7.2)
`
`-----------------------USE IN SPECIFIC POPULATIONS-----------------------­
` Nursing mothers: Discontinue drug or nursing, taking into consideration
`the importance of drug to the mother. (8.3)
` Hepatic impairment: For advanced HR+ BC, advanced PNET, advanced
`RCC, or renal angiomyolipoma with TSC patients with hepatic impairment,
`reduce AFINITOR dose. For SEGA patients with severe hepatic
`impairment, reduce the starting dose of AFINITOR Tablets or AFINITOR
`
`DISPERZ. (2.2, 2.3, 2.5, 5.10, 8.8)
`
`See 17 for PATIENT COUNSELING INFORMATION and
`
`FDA-approved patient labeling
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Revised: 09/2015
`
`
`
`
`
`
`
`
`Reference ID: 3822070
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 1 of 44
`
`

`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*


`1
`INDICATIONS AND USAGE

`1.1 Advanced Hormone Receptor-Positive, HER2-Negative Breast

`Cancer (Advanced HR+ BC)


`1.2 Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET)


`1.3 Advanced Renal Cell Carcinoma (RCC)


`1.4 Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC)

`1.5 Subependymal Giant Cell Astrocytoma (SEGA) with Tuberous

`Sclerosis Complex (TSC)


`2 DOSAGE AND ADMINISTRATION
`

`2.1 Recommended Dose in Advanced Hormone Receptor-Positive,
`HER2-Negative Breast Cancer, Advanced PNET, Advanced RCC,

`and Renal Angiomyolipoma with TSC

`2.2 Dose Modifications in Advanced Hormone Receptor-Positive,
`HER2-Negative Breast Cancer, Advanced PNET, Advanced RCC,

`and Renal Angiomyolipoma with TSC


`2.3 Recommended Dose in SEGA with TSC


`2.4 Therapeutic Drug Monitoring in SEGA with TSC


`2.5 Dose Modifications in SEGA with TSC


`2.6 Administration of AFINITOR Tablets in SEGA with TSC

`2.7 Administration and Preparation of AFINITOR DISPERZ in SEGA

`with TSC


`3 DOSAGE FORMS AND STRENGTHS


`3.1 AFINITOR (everolimus) Tablets
`


`3.2 AFINITOR DISPERZ (everolimus tablets for oral suspension)


`4 CONTRAINDICATIONS


`5 WARNINGS AND PRECAUTIONS


`5.1 Non-infectious Pneumonitis


`5.2
`Infections

`5.3 Angioedema with Concomitant Use of Angiotensin-Converting

`Enzyme (ACE) Inhibitors


`5.4 Oral Ulceration


`5.5 Renal Failure


`5.6
`Impaired Wound Healing


`5.7 Geriatric Patients


`5.8 Laboratory Tests and Monitoring


`5.9 Drug-drug Interactions


`5.10 Hepatic Impairment


`5.11 Vaccinations


`5.12 Embryo-fetal Toxicity


`6 ADVERSE REACTIONS

`6.1 Clinical Study Experience in Advanced Hormone Receptor-

`Positive, HER2-Negative Breast Cancer
`

`6.2 Clinical Study Experience in Advanced Pancreatic Neuroendocrine

`Tumors


`6.3 Clinical Study Experience in Advanced Renal Cell Carcinoma

`6.4 Clinical Study Experience in Renal Angiomyolipoma with

`Tuberous Sclerosis Complex

`6.5 Clinical Study Experience in Subependymal Giant Cell

`Astrocytoma with Tuberous Sclerosis Complex


`6.6 Postmarketing Experience


`7 DRUG INTERACTIONS


`7.1 Agents That May Increase Everolimus Blood Concentrations
`


`7.2 Agents That May Decrease Everolimus Blood Concentrations
`

`7.3 Drugs That May Have Their Plasma Concentrations Altered by
`
`
`

`Everolimus


`8 USE IN SPECIFIC POPULATIONS


`8.1 Pregnancy


`8.3 Nursing Mothers


`8.4 Pediatric Use


`8.5 Geriatric Use


`8.6 Females and Males of Reproductive Potential


`8.7 Renal Impairment


`8.8 Hepatic Impairment


`10 OVERDOSAGE


`11 DESCRIPTION


`12 CLINICAL PHARMACOLOGY


`12.1 Mechanism of Action


`12.2 Pharmacodynamics


`12.3 Pharmacokinetics


`12.6 QT/QTc Prolongation Potential


`13 NONCLINICAL TOXICOLOGY


`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility


`13.2 Animal Toxicology and/or Pharmacology


`14 CLINICAL STUDIES

`14.1 Advanced Hormone Receptor-Positive, HER2-Negative Breast

`Cancer


`14.2 Advanced Neuroendocrine Tumors


`14.3 Advanced Renal Cell Carcinoma


`14.4 Renal Angiomyolipoma with Tuberous Sclerosis Complex

`14.5 Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis

`Complex


`15 REFERENCES


`16 HOW SUPPLIED/STORAGE AND HANDLING


`17 PATIENT COUNSELING INFORMATION
`* Sections or subsections omitted from the full prescribing information are
`
`
`not listed
`
`
`
`Reference ID: 3822070
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 2 of 44
`
`

`
`
`
`
`
` FULL PRESCRIBING INFORMATION
`
`1
`
`
`INDICATIONS AND USAGE
`
`
`1.1
`Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (Advanced HR+ BC)
` AFINITOR® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2­
`
`negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or
`anastrozole.
`
`
`1.2
`Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET)
`AFINITOR® is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin
`
`(PNET) with unresectable, locally advanced or metastatic disease.
`
`AFINITOR® is not indicated for the treatment of patients with functional carcinoid tumors.
`
`
`
`Advanced Renal Cell Carcinoma (RCC)
`1.3
`AFINITOR® is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of
`treatment with sunitinib or sorafenib.
`
`Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC)
`1.4
`
`AFINITOR® is indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex
`
`
`(TSC), not requiring immediate surgery.
`The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective
`responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term
`outcomes.
`
`1.5
`Subependymal Giant Cell Astrocytoma (SEGA) with Tuberous Sclerosis Complex (TSC)
`AFINITOR® Tablets and AFINITOR® DISPERZ are indicated in pediatric and adult patients with tuberous sclerosis
`
`
`
`complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention
`but cannot be curatively resected.
`
`The effectiveness of AFINITOR Tablets and AFINITOR DISPERZ is based on demonstration of durable objective
`response, as evidenced by reduction in SEGA tumor volume. Improvement in disease-related symptoms and overall
`
`survival in patients with SEGA and TSC has not been demonstrated [see Clinical Studies (14.5)].
`
`DOSAGE AND ADMINISTRATION
`2
`AFINITOR is available in two dosage forms: tablets (AFINITOR Tablets) and tablets for oral suspension (AFINITOR
`DISPERZ).
` AFINITOR Tablets may be used for all approved indications.
` AFINITOR DISPERZ is approved for the treatment of patients with subependymal giant cell astrocytoma
`
`(SEGA) and tuberous sclerosis complex (TSC).
`
`Recommended Dose in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer, Advanced
`2.1
`PNET, Advanced RCC, and Renal Angiomyolipoma with TSC
`The recommended dose of AFINITOR Tablets is 10 mg, to be taken once daily at the same time every day. Administer
`
`either consistently with food or consistently without food [see Clinical Pharmacology (12.3)]. AFINITOR Tablets should
`be swallowed whole with a glass of water. Do not break or crush tablets.
`Continue treatment until disease progression or unacceptable toxicity occurs.
`
`
`
`
`
`Reference ID: 3822070
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 3 of 44
`
`

`
`
`Dose Modifications in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer, Advanced
`2.2
`PNET, Advanced RCC, and Renal Angiomyolipoma with TSC
`Adverse Reactions
`Management of severe or intolerable adverse reactions may require temporary dose interruption (with or without a dose
`reduction of AFINITOR therapy) or discontinuation. If dose reduction is required, the suggested dose is approximately
`
`
`50% lower than the daily dose previously administered [see Warnings and Precautions (5)].
`
`Table 1 summarizes recommendations for dose reduction, interruption or discontinuation of AFINITOR in the
`management of adverse reactions. General management recommendations are also provided as applicable. Clinical
`judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk
`
`assessment.
`
`Table 1: AFINITOR Dose Adjustment and Management Recommendation for Adverse Reactions
`Severitya
`AFINITOR Dose Adjustmentb and Management
`
`Adverse Reaction
`Recommendations
`No dose adjustment required.
`Initiate appropriate monitoring.
`
`Non-infectious
`pneumonitis
`
`
`
`
`
`
`
`Stomatitis
`
`
`
`
`
`
`
`Reference ID: 3822070
`
`Grade 1
`Asymptomatic,
`
`radiographic findings
`only
`Grade 2
`Symptomatic,
`
`not interfering with
`ADLc
`
`
`Grade 3
`
`Symptomatic,
`interfering with ADLc;
`O2 indicated
`
`Grade 4
`Life-threatening,
`ventilatory support
`indicated
`Grade 1
`Minimal symptoms,
`
`normal diet
`Grade 2
`Symptomatic but can eat
`and swallow modified
`diet
`
`Grade 3
`Symptomatic and unable
`to adequately aliment or
`hydrate orally
`
`
`Consider interruption of therapy, rule out infection and consider
`
`
`treatment with corticosteroids until symptoms improve to  Grade
`
`1.
`Re-initiate AFINITOR at a lower dose.
`
`Discontinue treatment if failure to recover within 4 weeks.
`Interrupt AFINITOR until symptoms resolve to  Grade 1.
`Rule out infection, and consider treatment with corticosteroids.
`Consider re-initiating AFINITOR at a lower dose. If toxicity
`
`recurs at Grade 3, consider discontinuation.
`
`
`Discontinue AFINITOR, rule out infection, and consider treatment
`with corticosteroids.
`
`No dose adjustment required.
`Manage with non-alcoholic or salt water (0.9%) mouth wash
`several times a day.
`
`Temporary dose interruption until recovery to Grade 1.
`
`Re-initiate AFINITOR at the same dose.
`If stomatitis recurs at Grade 2, interrupt dose until recovery to
`Grade 1. Re-initiate AFINITOR at a lower dose.
`Manage with topical analgesic mouth treatments (e.g., benzocaine,
`butyl aminobenzoate, tetracaine hydrochloride, menthol or phenol)
`with or without topical corticosteroids (i.e., triamcinolone oral
`paste).d
`
`Temporary dose interruption until recovery to Grade 1.
`
`Re-initiate AFINITOR at a lower dose.
`Manage with topical analgesic mouth treatments (i.e., benzocaine,
`butyl aminobenzoate, tetracaine hydrochloride, menthol or phenol)
`with or without topical corticosteroids (i.e., triamcinolone oral
`paste).d
`
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 4 of 44
`
`

`
`Discontinue AFINITOR and treat with appropriate medical
`therapy.
`
`
`
`
`
`
`
`
`Other non-
`hematologic toxicities
`(excluding metabolic
`events)
`
`Grade 4
`Symptoms associated
`with life-threatening
`consequences
`Grade 1
`
`Grade 2
`
`If toxicity is tolerable, no dose adjustment required.
`Initiate appropriate medical therapy and monitor.
`If toxicity is tolerable, no dose adjustment required.
`Initiate appropriate medical therapy and monitor.
`If toxicity becomes intolerable, temporary dose interruption until
`
`
`recovery to Grade 1. Reinitiate AFINITOR at the same dose.
`
`If toxicity recurs at Grade 2, interrupt AFINITOR until recovery to
`
`Grade 1. Reinitiate AFINITOR at a lower dose.
`
`Temporary dose interruption until recovery to Grade 1.
`Initiate appropriate medical therapy and monitor.
`Consider reinitiating AFINITOR at a lower dose. If toxicity recurs
`at Grade 3, consider discontinuation.
`
`Discontinue AFINITOR and treat with appropriate medical
`therapy.
`
`No dose adjustment required.
`Initiate appropriate medical therapy and monitor.
`No dose adjustment required.
`Manage with appropriate medical therapy and monitor.
`Temporary dose interruption.
`
`Reinitiate AFINITOR at a lower dose.
`Manage with appropriate medical therapy and monitor.
`Discontinue AFINITOR and treat with appropriate medical
`therapy.
`
`a Severity grade description: 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms; 4 = life-threatening
`
`
`symptoms.
`b If dose reduction is required, the suggested dose is approximately 50% lower than the dose previously administered.
`
`c Activities of daily living (ADL)
`d Avoid using agents containing alcohol, hydrogen peroxide, iodine, and thyme derivatives in management of stomatitis
`
`as they may worsen mouth ulcers.
`
`Hepatic Impairment
`Hepatic impairment will increase the exposure to everolimus [see Warnings and Precautions (5.10) and Use in Specific
`Populations (8.8)]. Dose adjustments are recommended:
` Mild hepatic impairment (Child-Pugh class A) – The recommended dose is 7.5 mg daily; the dose may be decreased
`to 5 mg if not well tolerated.
` Moderate hepatic impairment (Child-Pugh class B) – The recommended dose is 5 mg daily; the dose may be
`decreased to 2.5 mg if not well tolerated.
`
` Severe hepatic impairment (Child-Pugh class C) – If the desired benefit outweighs the risk, a dose of 2.5 mg daily
`
`
`may be used but must not be exceeded.
`
`Dose adjustments should be made if a patient’s hepatic (Child-Pugh) status changes during treatment.
`
`
`
`Grade 3
`
`Grade 4
`
`Grade 1
`
`Grade 2
`
`Grade 3
`
`Grade 4
`
`
`
`
`
`Metabolic events
`(e.g. hyperglycemia,
`dyslipidemia)
`
`
`
`
`
`
`
`
`
`Reference ID: 3822070
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 5 of 44
`
`

`
`
`
`CYP3A4/P-glycoprotein (PgP) Inhibitors
`Avoid the use of strong CYP3A4/PgP inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone,
`saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) [see Warnings and Precautions (5.9) and Drug
`Interactions (7.1)].
`
`Use caution when co-administered with moderate CYP3A4/PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant,
`erythromycin, fluconazole, verapamil, diltiazem). If patients require co-administration of a moderate CYP3A4 /PgP
`inhibitor, reduce the AFINITOR dose to 2.5 mg daily. The reduced dose of AFINITOR is predicted to adjust the area
`
`
`under the curve (AUC) to the range observed without inhibitors. An AFINITOR dose increase from 2.5 mg to 5 mg may
`be considered based on patient tolerance. If the moderate inhibitor is discontinued, a washout period of approximately 2 to
`3 days should be allowed before the AFINITOR dose is increased. If the moderate inhibitor is discontinued, the
`
`AFINITOR dose should be returned to the dose used prior to initiation of the moderate CYP3A4/PgP inhibitor.
`
`Grapefruit, grapefruit juice, and other foods that are known to inhibit cytochrome P450 and PgP activity may increase
`everolimus exposures and should be avoided during treatment.
`
`
`Strong CYP3A4/PgP Inducers
`
`Avoid the use of concomitant strong CYP3A4/PgP inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin,
`rifapentine, phenobarbital). If patients require co-administration of a strong CYP3A4/PgP inducer, consider doubling the
`daily dose of AFINITOR using increments of 5 mg or less. This dose of AFINITOR is predicted, based on
`pharmacokinetic data, to adjust the AUC to the range observed without inducers. However, there are no clinical data with
`this dose adjustment in patients receiving strong CYP3A4/PgP inducers. If the strong inducer is discontinued, consider a
`washout period of 3 to 5 days, before the AFINITOR dose is returned to the dose used prior to initiation of the strong
`CYP3A4/PgP inducer [see Warnings and Precautions (5.9) and Drug Interactions (7.2)].
`
`
`St. John’s Wort (Hypericum perforatum) may decrease everolimus exposure unpredictably and should be avoided.
`
`Recommended Dose in SEGA with TSC
`2.3
`The recommended starting dose is 4.5 mg/m2, once daily. The recommended starting dose for patients with severe hepatic
`impairment (Child-Pugh class C) or requiring moderate CYP3A4/PgP inhibitors is 2.5 mg/m2, once daily [see Dosage and
`
`Administration (2.5)]. The recommended starting dose for patients requiring a concomitant strong CYP3A4 inducer is
`9 mg/m2, once daily [see Dosage and Administration (2.5)]. Round dose to the nearest strength of either AFINITOR
`
`Tablets or AFINITOR DISPERZ.
`Do not combine AFINITOR Tablets and AFINITOR DISPERZ to achieve the desired total dose.
`
`Use therapeutic drug monitoring to guide subsequent dosing [see Dosage and Administration (2.4)]. Adjust dose at 2
`week intervals as needed to achieve and maintain trough concentrations of 5 to 15 ng/mL [see Dosage and Administration
`
`
`(2.4, 2.5)].
`Continue treatment until disease progression or unacceptable toxicity occurs. The optimal duration of therapy is unknown.
`
`Therapeutic Drug Monitoring in SEGA with TSC
`2.4
`Monitor everolimus whole blood trough levels routinely in all patients. When possible, use the same assay and laboratory
`
`for therapeutic drug monitoring throughout treatment.
`Assess trough concentrations approximately 2 weeks after initiation of treatment, a change in dose, a change in co­
`administration of CYP3A4/PgP inducers and/or inhibitors, a change in hepatic function, or a change in dosage form
`
`between AFINITOR Tablets and AFINITOR DISPERZ. Once a stable dose is attained, monitor trough concentrations
`every 3 to 6 months in patients with changing body surface area or every 6 to 12 months in patients with stable body
`
`
`surface area for the duration of treatment.
`Titrate the dose to attain trough concentrations of 5 to 15 ng/mL.
`
`  For trough concentrations less than 5 ng/mL, increase the daily dose by 2.5 mg (in patients taking AFINITOR
`Tablets) or 2 mg (in patients taking AFINITOR DISPERZ).
`
`
`
`Reference ID: 3822070
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 6 of 44
`
`

`
`
` For trough concentrations greater than 15 ng/mL, reduce the daily dose by 2.5 mg (in patients taking AFINITOR
`Tablets) or 2 mg (in patients taking AFINITOR DISPERZ).
` If dose reduction is required for patients receiving the lowest available strength, administer every other day.
`
`
`
`
`
`
`
`2.5
`Dose Modifications in SEGA with TSC
`
`Adverse Reactions
`Temporarily interrupt or permanently discontinue AFINITOR Tablets or AFINITOR DISPERZ for severe or intolerable
`adverse reactions. If dose reduction is required when reinitiating therapy, reduce the dose by approximately 50% [see
`Dosage and Administration (2.2) and Warnings and Precautions (5)]. If dose reduction is required for patients receiving
`
`
`the lowest available strength, administer every other day.
`
`Hepatic Impairment
`  Reduce the starting dose of AFINITOR Tablets or AFINITOR DISPERZ by approximately 50% in patients with
`
`SEGA who have severe hepatic impairment (Child-Pugh class C) [see Dosage and Administration (2.3)].
`Adjustment to the starting dose for patients with SEGA who have mild (Child-Pugh class A) or moderate (Child-
`Pugh class B) hepatic impairment may not be needed. Subsequent dosing should be based on therapeutic drug
`monitoring.
` Assess everolimus trough concentrations approximately 2 weeks after commencing treatment, a change in dose, or
`
`any change in hepatic function [see Dosage and Administration (2.3, 2.4)].
`
`
`CYP3A4/P-glycoprotein (PgP) Inhibitors
`
`Avoid the use of concomitant strong CYP3A4/PgP inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,
`nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) in patients receiving AFINITOR
`Tablets or AFINITOR DISPERZ [see Warnings and Precautions (5.9) and Drug Interactions (7.1)].
`
`For patients who require treatment with moderate CYP3A4/PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant,
`erythromycin, fluconazole, verapamil, diltiazem):
`
`  Reduce the AFINITOR Tablets or AFINITOR DISPERZ dose by approximately 50%. Administer every other day if
`
`
`dose reduction is required for patients receiving the lowest available strength and maintain trough concentrations of 5
`to 15 ng/mL [see Dosage and Administration (2.3, 2.4)].
`
`  Assess everolimus trough concentrations approximately 2 weeks after dose reduction [see Dosage and Administration
`
`(2.3, 2.4)].
`
`  Resume the dose that was used prior to initiating the CYP3A4/PgP inhibitor 2 to 3 days after discontinuation of a
`
`moderate inhibitor. Assess the everolimus trough concentration approximately 2 weeks later [see Dosage and
`Administration (2.3, 2.4)].
`
`Do not ingest foods or nutritional supplements (e.g., grapefruit, grapefruit juice) that are known to inhibit cytochrome
`
`P450 or PgP activity.
`
`
`Strong CYP3A4/PgP Inducers
`
`Avoid the use of concomitant strong CYP3A4/PgP inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin,
`rifapentine, phenobarbital) if alternative therapy is available [see Warnings and Precautions (5.9) and Drug Interactions
`
`
`(7.2)]. For patients who require treatment with a strong CYP3A4/PgP inducer:
` Double the dose of AFINITOR Tablets or AFINITOR DISPERZ and assess tolerability [see Dosage and
`
`
`Administration (2.3)].
` Assess the everolimus trough concentration 2 weeks after doubling the dose and adjust the dose if necessary to
`maintain a trough concentration of 5 to 15 ng/mL [see Dosage and Administration (2.3, 2.4)].
` Return the AFINITOR Tablets or AFINITOR DISPERZ dose to that used prior to initiating the strong CYP3A4/PgP
`inducer if the strong inducer is discontinued, and assess the everolimus trough concentrations approximately 2 weeks
`later [see Dosage and Administration (2.3, 2.4)].
`
`
`
`
`
`Reference ID: 3822070
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 7 of 44
`
`

`
`
`Do not ingest foods or nutritional supplements (e.g., St. John’s Wort (Hypericum perforatum)) that are known to induce
`cytochrome P450 activity.
`
`Administration of AFINITOR Tablets in SEGA with TSC
`2.6
`Do not combine the 2 dosage forms (AFINITOR Tablets and AFINITOR DISPERZ) to achieve the desired total dose. Use
`one dosage form or the other.
`Administer AFINITOR Tablets orally once daily at the same time every day. Administer either consistently with food or
`
`
`consistently without food [see Clinical Pharmacology (12.3)].
`AFINITOR Tablets should be swallowed whole with a glass of water. Do not break or crush tablets.
`
`2.7
`Administration and Preparation of AFINITOR DISPERZ in SEGA with TSC
`Wear gloves to avoid possible contact with everolimus when preparing suspensions of AFINITOR DISPERZ for another
`person.
`Do not combine the 2 dosage forms (AFINITOR Tablets and AFINITOR DISPERZ) to achieve the desired total dose. Use
`one dosage form or the other.
`
`Administer AFINITOR DISPERZ (everolimus tablets for oral suspension) as a suspension only.
`
`Administer AFINITOR DISPERZ orally once daily at the same time every day. Administer either consistently with food
`
`or consistently without food [see Clinical Pharmacology (12.3)].
`Administer suspension immediately after preparation. Discard suspension if not administered within 60 minutes after
`preparation.
`Prepare suspension in water only.
`
`Using an oral syringe:
`Place the prescribed dose of AFINITOR DISPERZ into a 10-mL syringe. Do not exceed a total of 10 mg per syringe.
`
`If higher doses are required, prepare an additional syringe. Do not break or crush tablets.
`
`  Draw approximately 5 mL of water and 4 mL of air into the syringe.
`Place the filled syringe into a container (tip up) for 3 minutes, until the AFINITOR DISPERZ tablets are in
`suspension.
`  Gently invert the syringe 5 times immediately prior to administration.
`
`  After administration of the prepared suspension, draw approximately 5 mL of water and 4 mL of air into the same
`
`
`syringe, and swirl the contents to suspend remaining particles. Administer the entire contents of the syringe.
`
`Using a small drinking glass:
`Place the prescribed dose of AFINITOR DISPERZ into a small drinking glass (maximum size 100 mL) containing
` 
`
`approximately 25 mL of water. Do not exceed a total of 10 mg of AFINITOR DISPERZ per glass. If higher doses are
`required, prepare an additional glass. Do not break or crush tablets.
` Allow 3 minutes for suspension to occur.
` Stir the contents gently with a spoon, immediately prior to drinking.
`
`
` After administration of the prepared suspension, add 25 mL of water and stir with the same spoon to re-suspend
`
`remaining particles. Administer the entire contents of the glass.
`
`
`
`3
`
`DOSAGE FORMS AND STRENGTHS
`
`
`AFINITOR (everolimus) Tablets
`3.1
`2.5 mg tablet
`White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with “LCL” on one side and
`
`“NVR” on the other.
`
`
`
`
`
`Reference ID: 3822070
`
`
`
`
`
`
`
`NOVARTIS EXHIBIT 2048
`Par v Novartis, IPR 2016-00084
`Page 8 of 44
`
`

`
`
`5 mg tablet
`
`White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with “5” on one side and “NVR”
`
`on the other.
`7.5 mg tablet
`
`White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with “7P5” on one side and
`“NVR” on the other.
`10 mg tablet
`
`White to slightly yellow, elongated tablets with a bevelled edge and no score, engraved with “UHE” on one side and
`“NVR” on the other.
`
`
`
`AFINITOR DISPERZ (everolimus tablets for oral suspension)
`3.2
`2 mg tablet for oral suspension
`
`White to slightly yellowish, round, flat tablets with a bevelled edge and no score, engraved with “D2” on one side and
`“NVR” on the other.
`3 mg tablet for oral suspension
`
`White to slightly yellowish, round, flat tablets with a bevelled edge and no score, engraved with “D3” on one side and
`“NVR” on the other.
`5 mg tablet for oral suspension
`
`White to slightly yellowish, round, flat tablets with a bevelled edge an

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket